Skip to main content
●+254 119 023975 support@dnalabskenya.com
Patient Portal LoginB2B / Doctor Portal
DNA LabsKenya
Medical information Clinical review pending

Cytogenetics

Oncomine Focus Panel PDL1

The Oncomine Focus Panel PDL1 test analyzes tumor tissue to identify genetic mutations and PDL1 protein expression, guiding personalized cancer treatment decisions. Requires a doctor's prescription.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Tumor tissue sample (e.g., biopsy, surgical resection). Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. Ensure the referring physician provides a clear clinical history and relevant pathology reports.
Test priceKSh 105,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Oncomine Focus Panel PDL1 test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us
01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Patients diagnosed with cancer.
  • ✓Patients considering cancer treatment options.
  • ✓Patients whose tumors may be eligible for immunotherapy.
  • ✓Patients with specific cancer types where PDL1 status is relevant.
  • ✓Patients seeking personalized cancer treatment guidance.
02

In plain language

What this test helps you understand

This test helps oncologists select the most appropriate cancer treatment by identifying specific genetic mutations and PDL1 expression levels in tumor tissue. It can guide decisions regarding targeted therapies and immunotherapy.
The Oncomine Focus Panel PDL1 test is an advanced diagnostic tool used in oncology to analyze tumor tissue. It identifies specific genetic mutations and biomarkers, including the PDL1 protein, which are crucial for determining the most effective cancer treatment strategies. Understanding these genetic markers allows healthcare providers to tailor treatments, potentially improving patient outcomes. This test utilizes next-generation sequencing (NGS) and immunohistochemistry (IHC) methods. It is recommended for patients diagnosed with cancer, particularly when considering treatment options or seeking to understand potential responses to immunotherapy. Discuss with your healthcare provider to determine if this test is appropriate for your situation. Results are interpreted by medical professionals and should be discussed with your doctor to understand their implications for your treatment plan.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. Ensure the referring physician provides a clear clinical history and relevant pathology reports.
SampleTumor tissue sample (e.g., biopsy, surgical resection). Confirm specific requirements with the laboratory before booking.
MethodologyNext-Generation Sequencing (NGS) and Immunohistochemistry (IHC).
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
The test analyzes the provided tumor tissue sample. Results may not reflect the entire tumor or potential metastatic sites. The clinical significance of some detected mutations may still be under investigation. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This test analyzes a tumor tissue sample to identify specific genetic mutations and the level of PDL1 protein expression, which helps guide personalized cancer treatment decisions.
It helps doctors understand the specific characteristics of a patient's cancer, potentially identifying eligibility for targeted therapies or immunotherapy, leading to more effective treatment.
A tumor tissue sample, typically obtained from a biopsy or surgery, is required for this test. Please consult your doctor regarding sample collection.
Turnaround time varies. Please contact the laboratory for the most current information.
Results are analyzed and interpreted by qualified medical professionals. Your doctor will discuss the findings and their implications with you.
Yes, this test requires a prescription from a qualified healthcare provider.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Catecholamines Plasma Test

Measures epinephrine and norepinephrine levels in plasma to help detect hormonal imbalances related to conditions like hypertension and anxiety. Confirm with the laboratory before booking.

Learn more →

Epstein-Barr Virus Early RNA EBERISH In Situ Hybridization Test

Detects Epstein-Barr Virus (EBV) RNA in tumor tissue to aid in the early diagnosis of EBV-related cancers like lymphomas and nasopharyngeal carcinoma.

Learn more →

CA Cyfra 211 Lung Cancer Marker Test

The CA Cyfra 21-1 Lung Cancer Marker Test measures a specific protein fragment in the blood that can be elevated in lung cancer. It aids in diagnosis and monitoring.

Learn more →

Breast Cancer ER PR HER2 Ki67

The Breast Cancer ER PR HER2 Ki67 test analyzes key markers in breast tumor tissue to guide personalized treatment decisions. It measures hormone receptors (ER, PR), HER2 protein, and the Ki-67 proliferation marker.

Learn more →
Chat on WhatsApp